Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: A systematic literature analysis by the EPOSS group

Journal of Rheumatology

Volumn 37, Issue 1, 2010, Pages 105-115

  Kowal Bielecka, Otylia ^a   Avouac, Jerome ^b   Pittrow, David ^c   Huscher, Doerte ^d   Behrens, Frank ^e   Denton, Christopher P ^f   Foeldvari, Ivan ^g   Humbert, Marc ^h   Matucci Cerinic, Marco ⁱ   Nash, Peter ^j   Opitz, Christian F ^k   Rubin, Lewis J ^l   Seibold, James R ^m   Strand, Vibeke ⁿ   Furst, Daniel E ^o   Distler, Oliver ^p  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b RDU   (France)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e German Rheumatism Research Center   (Germany)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g General Hospital Eilbek   (Germany)

^h HÔPITAL ANTOINE BÉCLÈRE   (France)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j Rheumatology Research Unit   (Australia)

^k German Red Cross Hospital   (Germany)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Clinical trials; Echo Doppler; Expert panel on outcomes measures in pulmonary arterial hypertension; Hypertension; Outcomes; Scleroderma; Systemic sclerosis

Indexed keywords

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTRUCT VALIDITY; CONTENT VALIDITY; CRITERION VARIABLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; FACE VALIDITY; FEASIBILITY STUDY; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; LUNG ARTERY PRESSURE; LUNG PRESSURE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SCLEROSIS; SYSTEMATIC REVIEW; VALIDATION PROCESS;

BLOOD PRESSURE; DATABASES, FACTUAL; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; REVIEW LITERATURE AS TOPIC; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 73549125552     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090661     Document Type: Article

References (51)

1. Hsu VW, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol 2008;35:458-65.
2. Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005;32:1273-8.
3. Mukerjee D, St. George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
4. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
5. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of diseases. Ann Intern Med 2000;132:425-34.
6. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:808-14.
7. Tugwell P, Bombardier C. A methodologic framework for developing end selecting endpoints in clinical trials. J Rheumatol 1982;9:758-62.
8. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, et al. EPOSS-Omeract Group for the other coauthors of the EPOSS-OMERACT group. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: Delphi consensus study with cluster analysis. Arthritis Rheum 2008;59:867-75.
9. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor M, Valentini G, Furst D. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
11. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
12. Kiatchoosakun S, Ungkasekvinai W, Wonvipaporn C, Tatsanavivat P, Foocharoen C, Suwannaroj S, et al. D-dimer and pulmonary arterial hypertension in systemic sclerosis. J Med Assoc Thai 2007;90:2024-9.
13. Mukerjee D, St. George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004;43:461-6.
14. Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, Remy-Jardin M, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007;34:1005-11.
15. Plastiras SC, Karadimitrakis SP, Kampolis C, Moutsopoulos HM, Tzelepis GE. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 2007;36:392-6.
16. Villalba WO, Sampaio-Barros PD, Pereira MC, Cerqueira EM, Leme CA Jr, Marques-Neto JF, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131:217-22.
17. Vonk MC, Sander MH, van den Hoogen FHJ, van Riel PLCM, Verheugt FWA, van Dijk APJ. Right ventricle Tei-index: A tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. Eur J Echocardiography 2007;8:317-21.
18. Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest 2006;36 Suppl 3:49-53.
19. Fisher MR, Mathai SC, Champion HC, Girgis RE, Housten-Harris T, Hummers L, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006;54:3043-50.
20. Hsiao SH, Lee CY, Chang SM, Lin SK, Liu CP. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging. J Am Soc Echocardiogr 2006;19:507-14.
21. Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol 2006;33:61-8.
22. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Boutin le TH, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006;54:184-91.
23. Hesselstrand R, Ekman R, Eskilsson J, Isaksson A, Scheja A, Ohlin AK, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology 2005;44:366-71.
24. Gindzienska-Sieskiewicz E, Kowal-Bielecka O, Kita J, Lisowska A, Domyslawska I, Musial W, et al. The occurrence of pulmonary hypertension in patients hospitalized in the Department of Rheumatology and Internal Diseases Medical University of Bialystok in years 2003-2004. Annales Academiae Bialostocensis 2005;509 Suppl:298-300.
25. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005;52:2125-32.
26. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003;30:2398-405.
27. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003;124:2098-104.
28. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
29. Ulanet DB, Wigley FM, Gelber AC, Rosen A. Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 2003;49:85-92.
30. Launay D, Hachulla E, Hatron PY, Goullard L, Onimus T, Robin S, et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol 2001;28:2252-6.
31. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology 2001;40:453-9.
32. Giunta A, Tirri E, Maione S, Cangianiello S, Mele A, De Luca A, et al. Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 2000;59:94-8.
33. Morelli S, Ferrante L, Sgreccia A, Eleuteri ML, Perrone C, De Marzio P, et al. Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis. Scand J Rheumatol 2000;29:236-42.
34. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
35. Murata I, Takenaka K, Yoshinoya S, Kikuchi K, Kiuchi T, Tanigawa T, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest 1997;111:36-43.
36. Simeon CP, Armadans L, Fonollosa V, Vilardell M, Candell J, Tolosa C, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997;56:723-8.
37. Battle RW, Davitt MA, Cooper SM, Buckley LM, Leib ES, Beglin PA, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-9.
38. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis. An analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
39. Candell-Riera J, Armadans-Gil L, Simeón CP, Castell-Conesa J, Fonollosa-Pla V, García-del-Castillo H, et al. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996;39:1138-45.
40. Murata I, Kihara H, Shinohara S, Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J 1992;56:983-91.
41. Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74.
42. Smith JW, Clements PJ, Levisman J, Furst D, Ross M. Echocardiographic features of progressive systemic sclerosis (PSS). Correlation with hemodynamic and postmortem studies. Am J Med 1979;66:28-33.
43. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
44. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
45. Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 2008;58:1803-9.
46. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001;104:779-82.
47. Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Müller KM, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007;38:893-902.
48. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
49. Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, Ross DJ, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008;102:1305-10.
50. Lee CY, Chang SM, Hsiao SH, Tseng JC, Lin SK, Liu CP. Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion. Echocardiography 2007;24:118-25.
51. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006;174:1034-41.